Clinical Trial: NCT06370416
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
Status:
ENROLLING BY INVITATIONPhase:
Phase 2| Lead Sponsor: | Henan Cancer Hospital |
| Information Provided By: | Henan Cancer Hospital |
| Last Update Posted: | 2026-01-28 |
Study Overview
Brief Summary
This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of tralazili before chemotherapy in patients with NSCLC.After pathological diagnosis of non-small cell lung cancer(NSCLC), 40 eligible subjects who met the inclusion criteria were screened and given a treatment regimen of trilaciclib before chemotherapy, after signing informed consent.
Official Title
Conditions
Intervention / Treatment
- Drug: Trilaciclib
Other Study ID Numbers
- HSKY002
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | Henan Cancer Hospital |
| Information Provided By: | Henan Cancer Hospital |
| Last Update Posted: | 2026-01-28 |
Study Overview
Brief Summary
This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of tralazili before chemotherapy in patients with NSCLC.After pathological diagnosis of non-small cell lung cancer(NSCLC), 40 eligible subjects who met the inclusion criteria were screened and given a treatment regimen of trilaciclib before chemotherapy, after signing informed consent.
Official Title
Conditions
Intervention / Treatment
- Drug: Trilaciclib
Other Study ID Numbers
- HSKY002